Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EUCR Eucrates Biomedical Acquisition (EUCR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Eucrates Biomedical Acquisition Stock (NASDAQ:EUCR) 30 days 90 days 365 days Advanced Chart Ad Behind the MarketsA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.Click here to get the ticker >>> Get EUCR alerts:Sign Up Key Stats Today's Range$10.02▼$10.0450-Day Range$10.04▼$10.2552-Week Range$9.87▼$10.25Volume12,700 shsAverage Volume2,287 shsMarket Capitalization$42.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEucrates Biomedical Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses to identify and acquire a business in the biomedical or healthcare-related industries in North America and Europe. The company was incorporated in 2020 and is based in New York, New York.Read More… A new way to play the AI boom (act before November 19) (Ad)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as little as $16 and a brokerage account.Click here to get the ticker >>> Receive EUCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address EUCR Stock News HeadlinesZymergen nears final chapter with Bankruptcy Court settlementMay 17, 2024 | bizjournals.comPsyence Biomedical Finalizes Strategic Merger AgreementFebruary 1, 2024 | msn.comRigged election? Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late. November 4, 2024 | Porter & Company (Ad)What's Going On With Emergent Biosolutions Stock?November 28, 2023 | msn.comMineralys Therapeutics, Inc.: Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne KarydasSeptember 15, 2023 | finanznachrichten.de8-K: Eucrates Biomedical Acquisition Corp.February 18, 2023 | marketwatch.comOcean Biomedical stock falls 26%, down 60% since SPAC mergerFebruary 18, 2023 | msn.comOcean Biomedical Debuts on Nasdaq, Shares Trading 11% LowerFebruary 16, 2023 | marketwatch.comSee More Headlines EUCR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Eucrates Biomedical Acquisition own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eucrates Biomedical Acquisition investors own include Sprott Focus Trust (FUND), Barrick Gold (GOLD), Meta Platforms (META), ETFMG Alternative Harvest ETF (MJX), New Zealand Energy (NZ), Strathcona Resources (SCR) and Shopify (SHOP). Company Calendar Today11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorUnclassified Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:EUCR CUSIPN/A CIK1822929 WebN/A Phone212-710-5220FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$2.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-62.82% Return on Assets2.95% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.81 per share Price / Cash Flow12.36 Book Value($1.25) per share Price / Book-8.03Miscellaneous Outstanding Shares4,210,000Free Float3,386,000Market Cap$42.27 million OptionableNot Optionable Beta-0.07 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:EUCR) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eucrates Biomedical Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eucrates Biomedical Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
